Squarepoint
COGT icon

Squarepoint’s Cogent Biosciences COGT Stock Holding History

Squarepoint’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,500
Closed -$488K – 4697
2024
Q4 		$488K Buy
+62,500
New +$623K ﹤0.01% 3742

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Squarepoint's COGT Position: Q1 2026 in Review

Squarepoint increased its Cogent Biosciences (COGT) stake by 45% in Q1 2026, buying an estimated $2.59M and bringing the position to 226,259 shares worth $8.71M. The position accounts for 0.01% of the portfolio, ranked #1147.

Squarepoint first reported a position in COGT in Q3 2018 and has held it in 14 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Squarepoint held 226,259 shares of Cogent Biosciences worth $8.71M as of Q1 2026.
  • Squarepoint bought 70,275 Cogent Biosciences shares in Q1 2026, an estimated $2.59M.
  • Cogent Biosciences made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1147 holding.
  • Squarepoint first reported a position in Cogent Biosciences in Q3 2018 and has held it in 14 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.